According to Sina Finance, Novartis expects steady sales growth through 2031, supported by existing marketed medicines and upcoming drug launches. Excluding foreign-exchange effects, the company forecasts annual sales growth of 5% from 2026 to 2031, compared with its previous guidance of 5% to 6% annually from 2025 to 2030.
Novartis raised peak-sales forecasts for Kesimpta, Scemblix and Leqvio. It said nine marketed products have potential peak annual sales of $3 billion to $10 billion each, while 10 late-stage drug candidates could reach peak sales in the billions of dollars after launch.
The company also reiterated its target to return its core operating margin to above 40% in 2029.